ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0306

Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry

Gabriela Schmajuk1, Nevin Hammam2, Jing Li3, David Collier4, Greg Kricorian5 and Scott Stryker6, 1UCSF / SFVA, San Francisco, CA, 2Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, 3University of California, San Francisco, San Francisco, CA, 4Amgen Inc., Simi Valley, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen Inc., San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), registry, rheumatoid arthritis, TNF-blocking Antibody

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management of RA in real-world settings are limited. Therefore, we examined the maintenance of remission (REM) or low DA (LDA) and treatment persistence in pts who switched from combination therapy (conventional synthetic [cs]DMARD + etanercept [ETN] or csDMARD + other TNF inhibitor [TNFi]) to monotherapy with either ETN or other TNFi.

Methods: A retrospective cohort study using Rheumatology Informatics System for Effectiveness (RISE) registry reported data for a 5-year period starting January 1, 2014. Pts (≥18 years) had a confirmed RA diagnosis by ≥2 International Classification of Diseases-9/10 diagnosis codes (≥30 days apart), with ≥1 diagnosis code before the index date (date of switch to monotherapy). They received combination of a csDMARD and a TNFi for ≥60 days and had ≥6 months (M) of follow-up on monotherapy. We assessed the proportion of pts who remained on ETN vs other TNFi monotherapy based on index date and prior exposure to non-TNFi biologic (b)DMARDs in the treatment persistence cohort. Pts who had documented DA scores before and after switching to monotherapy (≥30 days apart) and had achieved REM/LDA within 60 days prior to and up to 14 days after the index date were included in the DA maintenance cohort. Results are presented descriptively. Cumulative probability of being in REM/LDA and drug survival rates were estimated using Kaplan-Meier curves.

Results: Overall, 7399 pts were included in the treatment persistence cohort; 996 pts were included in the DA maintenance cohort, of whom 347 (34.8%) were on ETN and 649 (65.2%) were on other TNFi (adalimumab, infliximab, certolizumab pegol, or golimumab). The mean (SD) age of pts was 59.2 (14.80) years; most were female (78.1%), White (68.7%), and received MTX (75.1%) at baseline. The baseline demographics and clinical characteristics were comparable between ETN and other TNFi monotherapy groups (Table 1). During follow-up, most pts remained in REM/LDA, and the proportion who maintained REM/LDA based on CDAI was numerically higher in pts receiving ETN vs other TNFi (88.2% vs 80.5% and 78.8% vs 70.0% at 6 and 12 M, respectively; Fig 1a). Subgroup analyses stratified by baseline REM and LDA status showed that, for pts in REM at baseline, the proportion who maintained REM/LDA at follow-up was similar between groups; however, for pts with LDA at baseline, the proportion who maintained REM/LDA was numerically higher in pts receiving ETN vs other TNFi, especially at 12 M of follow-up (Fig 1b and 1c). In the treatment persistence cohort, persistence rates were similar between ETN and other TNFi groups at both timepoints (60.6% vs 61.3% and 43.8% vs 44.2% at 6 and 12 M, respectively; Fig 2). Subanalyses based on prior exposure to non-TNFi bDMARDs also showed similar persistence between groups; however, the persistence rates were lower for pts with prior exposure to non-TNFi bDMARDs (Fig 2).

Conclusion: Results from RISE showed better disease control among pts who switched from combination therapy to ETN than in those who switched to other TNFi monotherapies, despite similar persistence rates.

Supporting image 1

Table 1. Demographics and clinical characteristics of patients with baseline REM or LDA receiving ETN and other TNFi monotherapy after combination therapy [disease activity maintenance cohort]

Supporting image 2

Figure 1. Proportion of patients maintaining REM or LDA with ETN versus other TNFi monotherapy in the overall population (a), and in subgroup of patients with REM (b) or LDA (c) at baseline [disease activity maintenance cohort]

Supporting image 3

Figure 2. Patients who remained on ETN versus other TNFi monotherapy based on index date (a) and prior exposure to non-TNFi bDMARDs at 6 (b) and 12 months (c) [treatment persistence cohort]


Disclosures: G. Schmajuk, None; N. Hammam, None; J. Li, None; D. Collier, Amgen; G. Kricorian, Amgen; S. Stryker, Amgen.

To cite this abstract in AMA style:

Schmajuk G, Hammam N, Li J, Collier D, Kricorian G, Stryker S. Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/maintenance-of-disease-activity-and-treatment-persistence-in-patients-with-rheumatoid-arthritis-who-switched-from-combination-to-tnf-inhibitor-monotherapy-results-from-the-rheumatology-informatics-sy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/maintenance-of-disease-activity-and-treatment-persistence-in-patients-with-rheumatoid-arthritis-who-switched-from-combination-to-tnf-inhibitor-monotherapy-results-from-the-rheumatology-informatics-sy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology